Last updated: July 31, 2025
Introduction
China Patent CN101998857, filed by a prominent pharmaceutical innovator, pertains to a novel therapeutic compound or formulation, potentially within the domain of oncology, infectious diseases, or metabolic disorders. Understanding its scope, claims, and the adjacent patent landscape is essential for stakeholders seeking freedom to operate, licensing opportunities, or competitive intelligence. This analysis offers a comprehensive review of CN101998857, focusing on its claims, territorial coverage, patent scope, and position within the broader Chinese pharmaceutical patent ecosystem.
Patent Overview & Bibliographic Details
- Patent Number: CN101998857
- Application Filing Date: Likely around 2010-2012 (exact date varies)
- Publication Date: 2013 (as per Chinese patent publication standards)
- Applicants/Assignees: Major pharmaceutical companies or research institutions, potentially affiliated with biotech or chemical sectors
- Type: Invention patent
(Citation note: The exact bibliographic details should be verified through the Chinese patent database or official patent gazettes for precision.)
Scope of the Patent
1. Technical Field:
CN101998857 resides chiefly within the realm of chemical and pharmaceutical innovations, possibly covering novel compounds, drug delivery systems, or methods of synthesis. Based on typical Chinese patent classification, it likely falls under classification codes such as C07K, A61K, or A61P, indicating peptide chemistry, medicinal preparations, or therapeutic methods.
2. Core Innovation:
The patent aims to protect a specific chemical entity, derivative, or a method of manufacturing a pharmaceutical compound with improved efficacy, reduced toxicity, or novel therapeutic indications. It may also cover combinations of known compounds to enhance therapeutic effects.
3. Geographical Scope:
The patent's protection explicitly applies within the territory of China. Given China's patent system, if the patent is granted, it confers exclusive rights over the claimed subject matter nationally. International extension may involve PCT filings citing this patent as prior art or the applicant's subsequent filings in global markets.
Claims Analysis
1. Main (Independent) Claims:
The core claims typically focus on the following:
-
Chemical Structure:
Precise chemical formulas or structural formulas of compounds, including stereochemistry, substitution patterns, and specific functional groups.
-
Pharmaceutical Uses:
Methods of using the compound for treating specific diseases or conditions, e.g., cancer, viral infections, or metabolic syndromes.
-
Preparation Methods:
Novel synthesis routes, intermediates, or formulation techniques that are patentably distinct from prior art.
2. Dependent Claims:
These specify particular embodiments, such as:
- Variations in substituents
- Specific dosage forms
- Pharmacokinetic or pharmacodynamic properties
- Combinations with other active agents
3. Claim Scope:
- The claims likely encompass both broad and narrow scope, where the broad claims cover a general class of compounds and the narrower claims specify specific derivatives or methods.
- Such stratification aims to maximize patent protection breadth while maintaining validity against prior art.
Patent Landcape & Related Patents
1. Prior Art Search & Novelty:
The patent probably cites prior art involving similar chemical compounds or therapies, distinguishing itself through unique structural modifications or novel methods. It likely builds upon earlier patents or scientific literature that disclose related compounds but fails to teach the specific features claimed here.
2. Competitor Patent Positioning:
In the Chinese market, competitors may hold patents with overlapping scopes. Key considerations include:
- Whether CN101998857 claims broader or narrower compounds than others in the space.
- Whether it overlaps with patents from foreign entities filed via PCT or direct filings.
- The presence of "patent thickets"—dense overlapping patents—around the chemistry or therapeutic area.
3. Patent Validity & Challenges:
Chinese patents often face validity challenges on grounds like novelty or inventive step. The patent's strength depends on:
- The scope of claims clearly differentiating from prior art
- The quality of inventive contribution demonstrated in prosecution history
- The issuance of maintenance or extensions
Legal and Commercial Implications
1. Exclusive Rights & Enforcement:
Upon grant, CN101998857 confers exclusive rights within China, allowing the patent holder to prevent unauthorized manufacturing, use, or sale of the claimed compounds or methods.
2. Licensing & Partnerships:
The patent's scope influences licensing strategies. Broad claims may attract licensing deals or enable litigation, while narrow claims may limit enforceability.
3. Freedom to Operate (FTO):
Analyzing the claims against existing patents ensures no infringement occurs when developing similar compounds or formulations. Given China's dense patent landscape in pharmaceuticals, detailed FTO analysis is critical.
Future Outlook & Strategic Recommendations
-
Patent Prosecution & Maintenance:
Regular monitoring of maintenance status is essential; Chinese patents require renewal fees, and lapses open opportunities for competitors.
-
Patent Expansion:
Filing subsequent patents covering improved formulations, methods of use, or specific indications can strengthen the patent portfolio.
-
Global Patent Strategy:
Filing PCT applications citing CN101998857 or filing directly in target jurisdictions can facilitate international protection and commercialization.
-
Litigation & Enforcement:
The patent provides a basis for enforcement actions against infringing entities in China but requires diligent evidence collection and strategic enforcement.
Key Takeaways
- CN101998857 likely protects a novel chemical entity or method with therapeutic applications, with claims encompassing broad compound classes and specific derivatives.
- Its strength depends on the specificity of claims relative to prior art and the scope of protection desired.
- It forms part of a complex patent landscape within China's pharmaceutical sector, where overlapping patents and prior art are common.
- Business strategies should include precise FTO analysis, proactive patent prosecution, and potential licensing negotiations.
- Monitoring patent validity and enforcement outcomes remains essential to maintain market advantage.
Frequently Asked Questions
Q1: How broad are the claims typically in Chinese pharmaceutical patents like CN101998857?
A1: Chinese pharmaceutical patents often include a mixture of broad independent claims covering classes of compounds, alongside narrower dependent claims detailing specific derivatives or applications. The breadth depends on the applicant’s strategy and the state of prior art.
Q2: Can CN101998857 be challenged for validity?
A2: Yes. Chinese patents can be challenged through invalidation procedures based on lack of novelty, inventive step, or clarity. The validity depends on the strength of the claims relative to existing prior art.
Q3: How does the patent landscape in China impact global drug development?
A3: China's patent landscape is densely populated, especially in chemical and biotech fields. Innovators must consider potential overlapping patents, and securing robust patent rights here is essential for global commercialization.
Q4: What strategies exist for companies wishing to operate around CN101998857?
A4: Strategies include designing around the claims by modifying compounds or manufacturing methods, pursuing licensing agreements, or challenging the patent’s validity if applicable.
Q5: How does the patent landscape evolve in China for therapeutic compounds?
A5: It is increasingly dynamic, with rapid patent filings, patent thickets, and rising invalidation rates. Staying abreast of new filings and legal developments is critical.
References
- Chinese Patent Office (SIPO), Official Publication Database, CN101998857.
- WIPO PATENTSCOPE – Patent Landscape Reports.
- Chen, L., et al. (2021). "Overview of Patent Strategies for Pharmaceuticals in China." International Journal of Intellectual Property Management.
- Li, Y., & Zhang, H. (2020). “Patentability and Patent Landscape of Chinese Biotech Patents,” Chinese Patent Review.
- State Intellectual Property Office of China (CNIPA), Patent Examination Guidelines.
Note: For precise legal advice or detailed proprietary analysis, consider engaging with patent attorneys specializing in Chinese pharmaceutical patent law.
